Zelboraf Approved For Skin Cancer Treatment in the US

RocheThe US Food and Drug Administration have approved the Roche Holding AG's (ROG. VX) skin cancer medicine, Zelboraf that would assist in extending the life of the patients with melanoma.

The makers of the drug have claimed that the Zelboraf drug could provide better benefits then the chemotherapy by treating a gene transmutation, which is generally exposed in most of the patients with the disease.

Earlier in march, Yervoy (ipilimumab) was also approved by the US regulators and Zelboraf (vemurafenib) has been the second drug to get an approval.

Experts have notified, “The treatment only works in patients with advanced melanoma whose tumors express a gene mutation called BRAF V600E, meaning it could help about 10,000 patients in the United States”.

Melanoma Research Foundation Tim Turnham stated that a very few treatments for melanoma were available and even these treatments were not of much help in extending the life of patients. Mostly people with advanced melanoma pass away within 11 months of diagnosis.

Turnham added that these two drugs have been out after 13 years of nothing and the Zelboraf will work by blocking a protein that has been responsible for growth of cells.

However, the FDA has notified that the intake of drug could result into a few side effects like hair loss, joint pain, rash, fatigue, nausea and sensitivity to sun.